Transplantation of the lung

The introduction of cyclosporine as a highly effective immunosuppressive agent and the development of new techniques for heart-lung and lung transplantation have led to a new treatment for a wide range of fatal cardiopulmonary diseases. Indications for surgery are now becoming clear, together with major contra-indications. Suppurative lung disease, such as cystic fibrosis, can be effectively treated by heart-lung transplant (HLT). A whole new field of pulmonary medicine is emerging to provide the physiological monitoring and diagnostic techniques for major complications such as opportunistic lung infection and pulmonary rejection. Obliterative bronchiolitis, a consequence of frequent and severe rejection, still provides a major challenge to the immunological scientist and respiratory physician. Lung transplantation, by disrupting the vascular supply and innervation of the lung, is raising major questions about the generally accepted beliefs of regulation of breathing and pulmonary mechanics. Finally, as the survival rate improves beyond the current 50% at 3 yrs, lung transplantation will perhaps present further challenges to our understanding of the pathogenesis of various diseases such as asthma and cystic fibrosis.

This article has been cited by other articles:

				C. W. Barlow, R. C. Robbins, M. R. Moon, O. Akindipe, J. Theodore, and B. A. Reitz HEART-LUNG VERSUS DOUBLE-LUNG TRANSPLANTATION FOR SUPPURATIVE LUNG DISEASE J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 466 - 476. [Abstract] [Full Text] [PDF]